This acquisition has been in the news since I believe last August with board rejections and now it appears it has finally resolved and Genzyme will be purchased by Sanofi. This is a huge price tag at $20 Billion. You may or may not be familiar with Genzyme but back in 2009 they were in the...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Wed, Feb 16 2011
Filed under:
Filed under: Medically Related, Pharma/FDA News, drugs, healthcare, Pharma, Biotech, Massachusetts, Mergers and Acquisitions, Sanofi-Aventis, Genzyme, research and development collaboration
Well the patients in the US have to wait a little longer and it is amazing that in Europe as the title suggests has generics available. In May of 2010 Plavix was given a ruling by the FDA to establish a black box warning too. FDA Gives Plavix New Box Warning Relating to Metabolization in...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Wed, Jan 26 2011
Filed under:
Filed under: Medically Related, Pharma/FDA News, Pharma, Pills, FDA, Generic Drugs, Marketing, Patents, Europe, Plavix, Sanofi-Aventis, expire, Bristol-Myers Squibb
Algorithms can be programmed for many uses and this one seem so very impersonal with first a mass email effort that contained instructions to call in to a 800 number and a code. An automated voice according to this article told those who were going to be laid of to “stop working immediately” with...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Fri, Dec 17 2010
Filed under:
Filed under: Medically Related, Pharma/FDA News, drugs, Pharma, Code, Layoffs, Algorithms, Phone, Sanofi-Aventis, HR, drug reps, employees
The company states that BMP Sunstone is a Delaware corporation with Chinese subsidiary, subsidiary watch again. Sanofi is a well represented here in the US and is located in France. BMP also works with clinical trials, market research and pharmaceutical marketing for drugs in China to include...
The company is facing generic competition just like many of the other major pharmaceutical companies and also in the news they are attempting to purchase another biotech company, Genzyme. Sanofi Proposal to Acquire Genzyme Rejected–Looking for Other Alternatives Genzyme was probably not heard of by many...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Fri, Oct 8 2010
Filed under:
Filed under: Medically Related, Pharma/FDA News, Other Items of Interest, drugs, healthcare, Pharma, Biotech, FDA, Layoffs, contamination, virus, Sanofi-Aventis, Genzyme, Enzyme deficiencies, orphan drugs
60 Million tablets sounds like a lot of lot numbers for all to research. Last year when I began this little campaign I thought the number of recalls was going to grow and sure enough, just read the news every day. So to find the lot numbers visit the FDA website or the Bristol-Myers site...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Wed, Sep 29 2010
Filed under:
Filed under: Medically Related, Technology, Pharma/FDA News, drugs, healthcare, Health IT, Pharma, FDA, Blood Pressure, cell phones, Recalls, Sanofi-Aventis, Microsoft Tags, Bristol Myers Squibb, Avalide
If you are not familiar with the buy out earlier this year, check out the 2 links below to get up to date. It appears Sanofi sees an advantage here with getting clinical trials done overseas versus here in the US. We all know that diminishing clinical trials in the US are a big concern. ...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Thu, Jul 1 2010
Filed under:
Filed under: Medically Related, Pharma/FDA News, healthcare, Medical Devices, Pharma, clinical trials, China, Research and Development, Outsourcing, Sanofi-Aventis, i3, United Heatlhcare, WuXi App Tec, Charles River, ChinaGate, TargGen
As drugs continue to come off patents, so goes the the big revenue pots of the past. I don’t know exactly where all the economists are getting the “good” word today when companies continue to use technology to replace and do work that humans have done. I used this article in a prior post...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Wed, Apr 7 2010
Filed under:
Filed under: Medically Related, Pharma/FDA News, Pharma, Prescriptions, Generic Drugs, Marketing, Sales, Sanofi-Aventis, cutbacks, Ambien CR
I get a lot of mail and promotional information on email, but now it looks like one pharma company has decided that all the “residents” in the US postal service, or at least in some designated postal areas need to do something about potential Osteoporosis. It is not enough we are blasted all over...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Fri, Jan 22 2010
Filed under:
Filed under: Pharma/FDA News, My Commentaries, Pharma, Prescriptions, Marketing, Heatlhcare, Sanofi-Aventis, junk mail, Actonel, osteoporosis, Warner Chilcott
Is this “Black Monday” for many drug reps? I am guessing we will hear later as to how many reps actually lost their jobs at Sanofi. As you can read below there was a preview of this event just before Thanksgiving and at least the news didn’t ruin the holiday, or should I say this holiday...
This seems to be the trend today if you keep up with the pharma news. The website shows 5 major R and D locations in the US alone. It sounds like a new business model could be in the works here, working more with investing with small biotech companies and getting away from the block buster...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
Sun, Mar 8 2009
Filed under:
Filed under: Medically Related, Pharma/FDA News, drugs, healthcare, Pharma, Biotech, Budget Cuts, R and D, Business Models, blockbuster drugs, Sanofi-Aventis